Gilead makes antiviral drugs — the leading HIV treatments plus cancer therapies.
Gilead Sciences, Inc. (GILD) is expected to report earnings on Thursday, October 29, 2026, after the close. Estimated release time 16:04 ET. Consensus EPS estimate is $2.17.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-04 | Jun 2026 qtr | $-7.25 | $-6.75 | +6.9% | $7.80B |
| 2026-05-07 | Mar 2026 qtr | $1.91 | $2.03 | +6.3% | $6.96B |
| 2026-02-10 | Dec 2025 qtr | $1.81 | $1.86 | +2.8% | $7.92B |
| 2025-10-30 | Sep 2025 qtr | $2.13 | $2.46 | — | $7.77B |
| 2025-08-07 | Jun 2025 qtr | $1.96 | $2.01 | +2.6% | $7.08B |
| 2025-04-24 | Mar 2025 qtr | $1.78 | $1.81 | +1.7% | $6.67B |
| 2025-02-11 | Dec 2024 qtr | $1.74 | $1.90 | +9.2% | $7.57B |
| 2024-11-06 | Sep 2024 qtr | $1.53 | $2.02 | — | $7.54B |
GILD has beaten consensus EPS in 6 of its last 6 scored quarters.
GILD pays a quarterly dividend, currently yielding 2.22%.
| Ex-dividend date | Amount | Paid |
|---|---|---|
| 2026-09-15 | $0.82 | 2026-09-29 |
| 2026-06-15 | $0.82 | 2026-06-29 |
| 2026-03-13 | $0.82 | 2026-03-30 |
| 2025-12-15 | $0.79 | 2025-12-30 |
| 2025-09-15 | $0.79 | 2025-09-29 |
| 2025-06-13 | $0.79 | 2025-06-27 |